Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H26FN3O5 |
| Molecular Weight | 431.4573 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)C(=O)OC1CCN(CC1)C2=C3CC[C@H](C)N4C=C(C(O)=O)C(=O)C(C=C2F)=C34
InChI
InChIKey=OUXXDXXQNWKOIF-RYUDHWBXSA-N
InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
| Molecular Formula | C22H26FN3O5 |
| Molecular Weight | 431.4573 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Levonadifloxacin is the S-(-) isomer of the benzoquinolizine fluoroquinolone nadifloxacin and is two- to four-fold more active than the racemic mixture. Levonadifloxacin is a potent antibacterial agent against Gram-positive bacteria especially against methicillin resistance Staphylococcus aureus. It also possesses potent bactericidal activity against other resistant variants like quinolone-resistant Staphylococcus aureus, vancomycin and glycopeptide intermediate Staphylococcus aureus and vancomycin resistant Staphylococcus aureus. Intravenous dosage form developed to treat complicated skin and skin structure infections and has recently completed Phase III studies in India and Phase I studies in USA.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of metabolites of novel Anti-MRSA fluoroquinolone WCK 771 in mouse, rat, rabbit, dog, monkey and human urine using liquid chromatography tandem mass spectrometry. | 2019-07 |
|
| Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone. | 2019-01 |
|
| In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms. | 2018-11 |
|
| Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. | 2018-03 |
|
| In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types. | 2009-02 |
|
| Simple liquid chromatography-tandem mass spectrometry method for determination of novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771 in human serum. | 2007-02-01 |
|
| The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. | 2006-11 |
|
| Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. | 2006-10 |
|
| Validated chiral high-performance liquid chromatography method for a novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771. | 2006-03-03 |
|
| Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes. | 2005-12 |
|
| Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. | 2005-10 |
|
| Activity of the new quinolone WCK 771 against pneumococci. | 2005-01 |
|
| Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. | 2004-12 |
|
| In vitro activity of the new quinolone WCK 771 against staphylococci. | 2004-09 |
|
| Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. | 2004-08 |
|
| Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. | 2003-11 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:43:26 GMT 2025
by
admin
on
Mon Mar 31 18:43:26 GMT 2025
|
| Record UNII |
57B7E1D1TG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10192
Created by
admin on Mon Mar 31 18:43:26 GMT 2025 , Edited by admin on Mon Mar 31 18:43:26 GMT 2025
|
PRIMARY | |||
|
100000174709
Created by
admin on Mon Mar 31 18:43:26 GMT 2025 , Edited by admin on Mon Mar 31 18:43:26 GMT 2025
|
PRIMARY | |||
|
16734914
Created by
admin on Mon Mar 31 18:43:26 GMT 2025 , Edited by admin on Mon Mar 31 18:43:26 GMT 2025
|
PRIMARY | |||
|
706809-20-3
Created by
admin on Mon Mar 31 18:43:26 GMT 2025 , Edited by admin on Mon Mar 31 18:43:26 GMT 2025
|
PRIMARY | |||
|
57B7E1D1TG
Created by
admin on Mon Mar 31 18:43:26 GMT 2025 , Edited by admin on Mon Mar 31 18:43:26 GMT 2025
|
PRIMARY | |||
|
C166823
Created by
admin on Mon Mar 31 18:43:26 GMT 2025 , Edited by admin on Mon Mar 31 18:43:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|